Claims for Patent: 8,338,489

Summary for Patent: 8,338,489

Title:	Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract:	The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s):	Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Beno t (Bordeaux, FR)
Assignee:	Universite Victor Segalen--Bordeaux 2 (Bordeaux Cedex, FR)
Application Number:	12/599,266
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,338,489
Patent Claims:	1. A method for treating a hemangioma comprising administering a medicament comprising a beta blocker which is propranolol or a pharmaceutically acceptable salt thereof wherein the medicament is administered at a daily dose of less than or equal to 5 mg/kg of body weight of the patient. 2. The method of claim 1, wherein the hemangioma is a capillary hemangioma or capillary infantile hemangioma. 3. The method of claim 1, wherein the medicament is a syrup or an injectable solution. 4. The method of claim 1, wherein the medicament is for oral administration, and is selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms. 5. The method of claim 4, wherein the medicament for oral administration is a liquid formulation selected from the group consisting of solutions, syrups, suspensions, emulsions, and oral drops. 6. The method of claim 1, wherein the medicament is for buccal or sublingual routes. 7. The method of claim 1, wherein the medicament is for topical-transdermal administration. 8. The method of claim 7, wherein the medicament is for topical administration and is selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 9. The method of claim 1, wherein the medicament is for nasal administration. 10. The method of claim 1, wherein the medicament is for rectal administration. 11. The method of claim 1, wherein the medicament is for parenteral administration. 12. A method for treating a hemangioma comprising administering to a patient in need thereof a pharmaceutically acceptable and efficient dose of propranolol or a pharmaceutically acceptable salt thereof wherein the dose administered per day is less than or equal to 5 mg/kg of body weight of the patient. 13. The method of claim 12, wherein the dose administered per day is from 1 to 5 mg/kg of body weight of the patient. 14. The method of claim 12, wherein the hemangioma is a capillary hemangioma or capillary infantile hemangioma. 15. The method of claim 12, wherein the medicament is a syrup or an injectable solution. 16. The method of claim 12, wherein the medicament is for oral administration, and is selected from the group consisting of liquid formulations, oral effervescent dosage forms, oral powders, multiparticule systems, and orodispersible dosage forms. 17. The method of claim 16, wherein the medicament for oral administration is a liquid formulation selected from the group consisting of solutions, syrups, suspensions, emulsions, and oral drops. 18. The method of claim 12, wherein the medicament is for buccal or sublingual routes. 19. The method of claim 12, wherein the medicament is for topical-transdermal administration. 20. The method of claim 19, wherein the medicament is for topical administration and is selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 21. The method of claim 12, wherein the medicament is for nasal administration. 22. The method of claim 12, wherein the medicament is for rectal administration. 23. The method of claim 12, wherein the medicament is for parenteral administration.